Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.
Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. Dreyling M, et al. Among authors: zinzani p. Ann Oncol. 2013 Apr;24(4):857-77. doi: 10.1093/annonc/mds643. Epub 2013 Feb 20. Ann Oncol. 2013. PMID: 23425945 Free article.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. Younes A, et al. Among authors: zinzani pl. Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Ann Oncol. 2017. PMID: 28379322 Free PMC article. Review.
Safety of extended pirtobrutinib exposure in relapsed and/or refractory B-cell malignancies.
Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Roeker LE, et al. Among authors: zinzani pl. Acta Haematol. 2024 Jun 1. doi: 10.1159/000539587. Online ahead of print. Acta Haematol. 2024. PMID: 38824917
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Dreyling M, et al. Among authors: zinzani pl. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2. Lancet. 2024. PMID: 38705160 Free article. Clinical Trial.
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, Gori D, Masetti R, Stefoni V, Bonifazi F, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: zinzani pl. Ann Hematol. 2024 May 2. doi: 10.1007/s00277-024-05766-0. Online ahead of print. Ann Hematol. 2024. PMID: 38695872
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review.
Criscuolo M, Tosti ME, Broccoli A, Varettoni M, Maraglino AME, Anastasia A, Cantonetti M, Trentin L, Kovalchuk S, Orsucci L, Deodato M, Spolzino A, Volpetti S, Annibali O, Storti S, Stelitano C, Marchesi F, Morè S, Fianchi L, Falini B, Pulsoni A, Tiacci E, Zinzani PL, Pagano L. Criscuolo M, et al. Among authors: zinzani pl. Cancers (Basel). 2024 Apr 11;16(8):1475. doi: 10.3390/cancers16081475. Cancers (Basel). 2024. PMID: 38672557 Free PMC article.
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy.
Pensato U, Pondrelli F, de Philippis C, Asioli GM, Crespi A, Buizza A, Mannina D, Casadei B, Maffini E, Straffi L, Marcheselli S, Zinzani PL, Bonifazi F, Guarino M, Bramanti S. Pensato U, et al. Among authors: zinzani pl. Neurol Sci. 2024 Apr 4. doi: 10.1007/s10072-024-07510-y. Online ahead of print. Neurol Sci. 2024. PMID: 38573433 No abstract available.
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles G, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano J, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ. Zinzani PL, et al. Blood Adv. 2024 May 28;8(10):2400-2404. doi: 10.1182/bloodadvances.2023011030. Blood Adv. 2024. PMID: 38531062 Free PMC article. No abstract available.
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy.
Pensato U, Pondrelli F, de Philippis C, Asioli GM, Crespi A, Buizza A, Mannina D, Casadei B, Maffini E, Straffi L, Marcheselli S, Zinzani PL, Bonifazi F, Guarino M, Bramanti S. Pensato U, et al. Among authors: zinzani pl. Neurol Sci. 2024 Mar 21. doi: 10.1007/s10072-024-07481-0. Online ahead of print. Neurol Sci. 2024. PMID: 38512531
769 results